BioCanna Health Care

BioCanna Health Care was a Canadian healthcare and biotechnology company focused on pharmaceutical applications of cannabinoids, terpenes, and other biomaterials. Publicly available company materials describe R&D efforts in anti-inflammatory and neurological disorder drug development, alongside a COVID-19 point-of-care saliva antigen test developed through its subsidiary BioCanna CuraLab. The company also announced a BioNano Virus Detection System platform and a research collaboration with the University of Ottawa. However, there is very limited current public evidence of ongoing operations, recent financing, product approvals, or an active corporate presence, suggesting the business is likely inactive as of 2026.